Trade Name “Bank” Proposed For Neutral/Extreme Controls In FDA Pilot
This article was originally published in The Pink Sheet Daily
FDA’s proposal includes limited number of control names.
You may also be interested in...
Industry wonders whether its pilot submissions hold weight against agency evaluations.
Firms lack explicit incentives to participate in the proposed self-evaluation, which will be discussed at a public meeting June 5-6.
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.